<DOC>
	<DOCNO>NCT00333645</DOCNO>
	<brief_summary>This non-comparative , open , multisite prospective estimation study evaluate efficacy safety caspofungin prophylactic treatment adult receive orthotopic liver transplant high risk develop invasive fungal infection . It expect proportion high-risk liver transplant recipient develop document ( proven probable per European Organization Research Treatment Cancer/Mycoses Study Group [ EORTC/MSG ] modify criterion ) invasive fungal infection first 100 day onset prophylaxis caspofungin lower 15 % . It also expect incidence serious drug-related adverse event le 25 % .</brief_summary>
	<brief_title>Prophylaxis With Caspofungin High-Risk Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>18 year age old Patient receive orthotopic liver transplantation Patient meet criterion , define per protocol , consider high risk develop invasive fungal infection postliver transplantation For woman childbearing potential , patient must negative serum urine pregnancy test Any systemic antifungal therapy ( fluconazole maximum 7 day ) within 14 day administration study drug . Documented ( proven/probable ) suspect ( possible ) invasive fungal infection time enrollment . Abnormal laboratory value define per protocol . Allergy , hypersensitivity , serious reaction echinocandin antifungal . Patient expect survive least 5 day . Patient pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Liver transplantation</keyword>
	<keyword>Invasive fungal infection</keyword>
	<keyword>Invasive aspergillosis</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Caspofungin</keyword>
</DOC>